Buy MOTS-C 40 mg in Australia
MOTS-C 40 mg is a research-grade peptide that is studied at the AMPK energy-sensing pathway, supplied in Australia by Australian Research Peptides (ARP). Every batch is HPLC-tested; no certificate is published for this strength yet. This 40 mg vial is out of stock today; ARP ships from within Australia to all states and territories. For in vitro research purposes only.
Mitochondrial Research · Lyophilised Powder · Batch-tested · SKU 58106
$149.99
Presentation
40 mg per vial
Grade
High-Purity Research Grade
Form
Lyophilised Powder
Category
Mitochondrial Research
This strength is not in stock — stocked lines dispatch same business day before 2pm AEST, Mon–Fri
Tracked shipping Australia-wide · typically 1–2 business days to most areas by Express Post · free post over $199, free Express over $299
For in vitro research purposes only. Not for human consumption. Not for animal consumption. This product is not a drug, food, cosmetic, or dietary supplement. No medical, therapeutic, or dosing information is provided.
Frequently Bought Together
About MOTS-C 40 mg
Coded inside mitochondrial DNA rather than the nucleus, its sixteen-amino-acid chain is studied in energy-metabolism research alongside the AMPK signalling pathway. This is the 40 mg MOTS-C vial, the largest of three, listed as 58106.
Nothing is published for the 40 mg size yet — MOTS-C lots go through HPLC, and the certificate follows.
In vitro energy metabolism research purposes only. Australian Research Peptides does not supply MOTS-C for human or veterinary use.
MOTS-C is studied in relation to energy metabolism, meaning how cells make and spend energy. Published work in mice and in cell culture reports it switching on AMPK, a protein that senses when a cell is short of fuel. Skeletal muscle looks like its main target tissue. This page names the research field and the measurements taken, and reports no outcome in a person.
The peptide is coded by a short stretch of the 12S ribosomal RNA gene, which sits inside mitochondrial DNA rather than in the nucleus. Peptides coded that way are grouped together as mitochondrial-derived peptides. Humanin was the first of the group to be described, and MOTS-C followed it. The name is written and searched as MOTS-C, MOTSc and MOTS C.
Lee and colleagues first described MOTS-C in 2015 in Cell Metabolism, identifying the reading frame it is coded from and the AMPK signalling pathway it was tested against in cells and in mice. ARP reports the existence of that published record and claims nothing about the material in its own vials.
Australian Research Peptides lists MOTS-C in Australia in three vial strengths, 10 mg, 20 mg and 40 mg, as a freeze-dried powder in a tamper-evident glass vial. It is searched as MOTS-C, MOTSc, MOTS C and the compressed motsc, and as a mitochondrial or longevity peptide. Stock is held locally and posted to every state and territory, so an order does not wait on an overseas consignment. Each batch is assayed by HPLC, and the CoA library sets out which strengths have a certificate published.
Further reading on MOTS-C: MOTS-C Research: What Studies Show and What Is Still Unknown · Why Research Peptides Come in Vials and Not Pens
MOTS-C 40 mg specifications, storage and shipping
- Compound: MOTS-C
- Quantity: 40 mg
- SKU: 58106
- Presentation: sealed glass vial
- Form: Lyophilised Powder
- Grade: High-purity research grade
- Purity verification: HPLC-assayed on every batch to a minimum of 99% purity — the measured result for your batch is stated on its Certificate of Analysis
- Identity confirmation: Mass spectrometry
- Classification: In vitro research purposes only — laboratory reference material
- Lyophilised — long term
- −20 °C to −80 °C — long-term storage
- Lyophilised — short term
- 2–8 °C — refrigerated, for a few months
- Reconstituted
- 2–8 °C — use within 8–12 weeks
Every batch undergoes HPLC purity analysis and mass-spectrometry identity confirmation. No laboratory report is published for this strength yet. The COA library lists every product and strength, and says which reports are available.
This strength is not in stock today. Stocked lines ordered before 2pm AEST on a business day are dispatched the same day with tracked shipping. Standard delivery within Australia typically takes 2–5 business days. See Shipping & Delivery for details, and follow your parcel on the Track Order page.
For in vitro research purposes only. Not for human consumption. Not for animal consumption. Not a drug, food, cosmetic, or dietary supplement. No therapeutic or medical claims are made.
Questions about MOTS-C 40 mg
Questions about MOTS-C 40 mg
Australian Research Peptides (ARP) sells MOTS-C 40 mg in Australia under 58106, at $149.99. Standard tracked post and Express Post carry MOTS-C 40 mg to all states and territories.
MOTS-C 40 mg is $149.99 a vial (58106). Two 40 mg vials come to $299.98.
Four 10 mg MOTS-C vials cost $359.96; one 40 mg vial is $149.99 — $209.97 less, and three fewer vials to store.
Per milligram, MOTS-C 40 mg works out to about $3.75 — $149.99 across 40 mg. The 10 mg MOTS-C vial works out to about $9.00 a milligram.
Not on its own. MOTS-C 40 mg is $149.99, $49.01 under $199. MOTS-C clears it with two 40 mg vials. MOTS-C's 20 mg vial falls short too.
$162.98 delivered in Australia. MOTS-C 40 mg is $149.99, plus $12.99 for 58106 by Standard tracked post. Express Post makes 58106 $166.98.
Two vials of MOTS-C. At $149.99 each, two 40 mg vials make $299.98 — past $299, so 58106 ships free by Express Post, costing $299.98.
Australian Research Peptides publishes no fill volume for 58106, so the amount is a decision for the work rather than one the listing sets. 58106 is 40 mg of dry MOTS-C: what the water changes is the solution, never the 40 mg sealed in the glass.
Forty milligrams of lyophilised MOTS-C, sealed dry in one glass vial with no water, filler or carrier beside it — four times the 10 mg listing and twice the 20 mg. It is the one MOTS-C strength where the dry cake is large enough to look like something, which is the opposite of the complaint the smallest vial attracts.
That is the researcher's own arithmetic, and the number worth knowing first is that 40 mg taken to 10 mg/mL needs 4 mL — more than a single 3 mL bacteriostatic water bottle holds. Australian Research Peptides publishes no fill volume and advises none; a smaller volume simply gives a stronger solution from the same glass.
One 40 mg MOTS-C vial holds the same peptide mass as four 10 mg vials, and handles nothing like them. Forty milligrams under one seal is one lot number, one make-up and one storage history, where four smaller vials are four of each. Against that, opening the 40 mg commits the whole quantity to a single refrigerated window, so it suits work that will genuinely use it inside that window.
MOTS-C is a peptide of sixteen amino acids that mitochondria code for themselves. Almost every other peptide in a cell is coded by DNA in the nucleus. This one is coded by DNA inside the mitochondrion, the compartment that generates most of a cell's energy. Researchers first described it in 2015. Australian Research Peptides supplies it as a dry cake, for laboratory work only.
MOTS-C stands for mitochondrial open reading frame of the 12S ribosomal RNA type-c. The name records a position in the genome rather than a chemical description. An open reading frame is a run of genetic code that can be read as instructions for a peptide, and MOTS-C is classed as a mitochondrial-derived peptide.
MOTS-C is studied at AMPK, the switch a cell throws when energy runs short. Lee's 2015 Cell Metabolism report describes it blocking part of the folate cycle, which builds up a molecule called AICAR, and AICAR turns AMPK on. Kim 2018, in the same journal, found that under metabolic stress the peptide also moves into the nucleus within about thirty minutes, where it binds antioxidant response elements — the stretches of DNA that switch stress-response genes on — and changes how strongly those genes are read. These are findings in cells and in mice.
Most MOTS-C work is done in cultured cells and in mice, and it is mechanistic rather than clinical. Lee and colleagues characterised the peptide in Cell Metabolism in 2015 and placed it on the AMPK signalling pathway; Reynolds and colleagues followed in Nature Communications in 2021, measuring the peptide in human muscle tissue samples. The published record stops at those model systems. None of that literature establishes anything about the research material on this page.
MOTS-C is not supplied as a tablet, a capsule or a nasal spray by Australian Research Peptides, which lists it only as a freeze-dried powder in a sealed glass vial. The published record on this peptide is built in cell culture and in animal models, not on an oral or intranasal preparation. No regulator anywhere has approved a MOTS-C product in any form, so no tablet exists as an approved medicine either. A pre-mixed presentation has also spent part of its stability window before it is posted, where a sealed lyophilisate starts that window when the researcher makes it up.
A MOTS-C vial holds freeze-dried peptide and nothing beside it. The solid is white to off-white, and all of it is the peptide rather than peptide spread through a filler. The glass is sealed under a tamper-evident cap. Nothing is dissolved, blended or split before dispatch, and the seal stays closed until a laboratory opens it.
No pharmacokinetic profile has been published for MOTS-C — nobody has measured how fast it is absorbed, spread or cleared. Santhanam's 2026 rat-heart paper in Naunyn-Schmiedeberg's Archives of Pharmacology closes by calling for pharmacokinetic studies, which is an admission that none exist. Australian Research Peptides publishes no clearance figure and will not estimate one. What ARP does record for every batch is the HPLC assay result. ARP's CoA library sets out which strengths have a certificate published against them.
MOTS-C is sixteen amino acids long, and the sequence PubChem records for CID 146675088 runs Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg. Gao's 2023 review in Metabolites reports the first eleven positions as highly conserved between species. Residue is the technical word for one amino-acid unit in a chain, so sixteen residues and sixteen amino acids describe the same thing. Both Australian Research Peptides vial sizes hold that identical chain.
The published MOTS-C record stops at cultured cells and mice, so there is no clinical evidence to weigh either way. What exists instead is laboratory work on how the molecule behaves inside a cell, built around the AMPK signalling pathway, and it is a genuinely interesting molecule with real preclinical work behind it. Australian Research Peptides supplies the peptide for in vitro research and makes no claim about what it does.
No published study answers this, because the MOTS-C record stops at cultured cells and mice and nothing further has been measured. The animal and cell-culture literature tracks signalling changes over hours to weeks under laboratory conditions, which is a different question entirely. Any specific timeframe quoted for this compound is invented, and Australian Research Peptides does not quote one.
It records nothing, because no published study has observed anything after exposure ended. Work on this mitochondrial peptide is barely a decade old and is confined largely to mice and cultured cells, all measured during the experiment itself. Nothing has been documented in either direction, and the candid position is that the question has never been examined.
Yes — MOTS-C at ten milligrams presents as a slight pale deposit that plenty of buyers overlook completely, while the twenty-milligram vial holds double and the forty-milligram four times as much, reading far more obviously as a cake. Sixteen amino acids of dried peptide simply do not fill much volume. No MOTS-C strength has filler or carrier added, which is precisely why so little sits there to look at.
Australian Research Peptides publishes storage conditions for MOTS-C rather than an expiry date, so no sealed shelf-life figure appears on this page and none should be carried across from a figure printed elsewhere. The storage panel gives the sealed dry vial two valid homes — frozen for the long term, or refrigerated for a few months — and gives a solution made up from it a shorter window of its own. Those are physical states rather than a choice between numbers. How long a correctly held lyophilisate lasts depends on the conditions it was actually kept in, which is why the conditions are what get published.
MOTS-C carries two methionines and a tryptophan, and those amino acids oxidise more readily than the others. Bachem's handling guidance keeps a lyophilisate dry and tightly closed below -15 °C, and prefers colder again for the long term. Cold glass pulls water out of the air. Stand the sealed vial in a desiccator until it is no longer cold, then unseal it. Solutions keep poorly, so freeze them in single-use aliquots.
Add bacteriostatic water to a MOTS-C vial and let the powder dissolve fully. Run the liquid in slowly and never shake the glass. MOTS-C is a basic peptide, so a mildly acidic buffer helps if water alone is slow to bring it into solution. Australian Research Peptides publishes no fill volume for any MOTS-C vial, because the volume added is what sets the concentration: each strength reaches 10 mg/mL at its own volume — 1 mL for the 10 mg, 2 mL for the 20 mg, 4 mL for the 40 mg.
Once dissolved, MOTS-C gets a 2–8 °C fridge and no more than twelve weeks in it under Australian Research Peptides' storage panel. That window belongs to the solution alone; a sealed dry vial is a different state with its own rows on the same panel. MOTS-C holds two methionines plus a tryptophan, among the residues most readily oxidised, so it has more to lose to air and light than a shorter chain. Keep it dark throughout, and divide it rather than entering one vial repeatedly.
Air is the ordinary culprit in a cloudy MOTS-C vial. Swirling or inverting it repeatedly forces bubbles through the liquid, and those scatter light indistinguishably from real turbidity before dispersing once everything is left alone. The twenty-milligram strength needs longer to finish clearing than the ten does, being twice the solid, and the forty longer again. Anything opaque beyond that, or grit which will not shift, is not simply bubbles.
Yes, bacteriostatic water is the diluent normally used with a MOTS-C vial. In this context a diluent turns dry powder into something a pipette can move. Dry powder is all that sits inside the glass, with no water and no carrier beside it. Australian Research Peptides catalogues the two apart, MOTS-C under Mitochondrial Research and the water under Lab Supplies.
Australian Research Peptides sells MOTS-C for in vitro research purposes only, and not as a medicine. It is not supplied for use in people or in animals, and no ARP material describes such use. MOTS-C is a research compound rather than an approved treatment, and it has not been assessed for that purpose. Anyone buying it takes responsibility for the rules that govern their own work.
MOTS-C has been approved by no drug regulator in any country, and no registered medicine contains it. Lee and colleagues only described this mitochondrial-encoded peptide in 2015, so its scientific record is short and almost wholly preclinical, and none of it has been submitted for review. A vial of it is unregistered material intended for laboratory experiments.
MOTS-C is prohibited in sport at all times, which is what a drug-testing question about it turns on. The World Anti-Doping Agency list names mitochondrial open reading frame of the 12S rRNA-c in full, unusually, grouping it with AICAR as an AMPK activator among the metabolic modulators. Prohibition applies in and out of competition alike. Sport Integrity Australia oversees testing for Australian athletes.
No MOTS-C batch is sold untested. HPLC measures how pure the peptide is. Mass spectrometry checks that the mass matches a sixteen-amino-acid chain, and a chain missing even one amino acid weighs something different. No salt form is published, because it is not confirmed for this material. No matching certificate is currently published for this product and strength.
MOTS-C has no separate development code or trade name. Registries index it under CAS 1627580-64-6, as a mitochondrial-derived peptide (MDP), and by its single-letter sequence MRWQEMGYIFYPRKLR. Buyers also type it compressed, as motsc or motsc10 with the vial size run straight on, and as MOTSc or MOTS C. It is sometimes nicknamed "exercise in a bottle" in headlines; that phrase is informal and does not establish a result, especially because nearly all the research described here is in rodents and the human studies measured the body's own MOTS-C.
MOTS-C is called a longevity peptide because of where it is coded and what it is studied against, not because any study has shown supplied peptide extending a life. It belongs to the mitochondrial-derived peptides, and mitochondrial function is one of the standard axes of ageing research, so writers and sellers file it under longevity. The published MOTS-C work itself measures energy metabolism and AMPK signalling, in cultured cells and in mice. No lifespan result in a person stands behind the label.
MOTS-C differs from semaglutide and retatrutide in molecular target rather than in degree. Semaglutide and retatrutide are incretin analogues — copies of the gut hormones a meal releases — built around the GLP-1 receptor, and retatrutide also binds the GIP and glucagon receptors. MOTS-C is coded inside mitochondria, is sixteen amino acids long, and is studied instead at the signals a cell uses to manage its own fuel supply. Different molecular class, different receptor targets, different research areas.
Australian Research Peptides lists MOTS-C; Chemist Warehouse does not stock it, and no pharmacy in any market does. The mitochondrial-derived peptide is not registered as a medicine anywhere in the world, which forecloses retail pharmacy supply everywhere rather than only in Australia. There is no prescription version either, because a prescription needs a registered product standing behind it. ARP offers it in three research vial sizes, 10 mg, 20 mg and 40 mg.